Detailed price information for Allogene Therapeutics Inc (ALLO-Q) from The Globe and Mail including charting and trades.
Preclinical milestone for selection and approval of first compound for lead optimization has been achievedFurther development validates the ...
Preclinical milestone for selection and approval of first compound for lead optimization has been achievedFurther development validates the potential intended mechanistic effect of CUE-501 for T cell- ...
Two-year disease-free survival from evaluable Phase 2 patients expected by the end of Q1 2028.Strasbourg, France, April 13, 2026, 8:00 a.m. CET – ...
MySA recently looked at the digital shift happening at H-E-B gas pumps. Instead of a few physical buttons, newer pumps are ...
Overcoming efficacy, safety, and manufacturing hurdles through innovative personalized cancer vaccine design ...
Transgene and NEC Bio ink agreement to prepare the next steps of the development of TG4050 in head and neck cancer: Strasbourg, France Monday, April 6, 2026, 17:00 Hrs [IST] Trans ...
The American Association for Cancer Research (AACR) will honor the following cancer researchers and physician-scientists during the AACR Annual Meeting 2026, to be held April 17-22 at the San Diego ...
Patients are seeking help from cadavers for these innovative fat transfers ...
Transgene’s updated analyst narrative keeps the fair value price target anchored at €1.10, indicating that the headline valuation marker is unchanged in the latest refresh. Bullish and bearish ...
Year to date, the Model Shadow Stock Portfolio is up 12.0%, dramatically outperforming the major indexes. The S&P 500 is down 4.3% year to date, while mid-cap and small-cap indexes are modestly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results